What a 14-Day Heart Monitor Catches After TAVR

What Is TAVR and Why Does the Heart Need Monitoring After?

TAVR (transcatheter aortic valve replacement) replaces a worn-out heart valve using a thin tube instead of open surgery. It helps older or sicker patients who cannot survive open surgery. Over the past 20 years, TAVR has saved many lives.¹

Quick answer: post tavr ecg monitoring is used because conduction defects and atrial arrhythmias can appear after discharge, not only during the procedure or immediate inpatient window. A 14-day ambulatory ECG protocol can capture intermittent rhythm events that shorter Holter or telemetry periods may miss.

post tavr ecg monitoring

Use this section as a practical validation check before interpreting the signal in a clinical, research, or operational workflow.

Verification checklist

• Risk-stratify by baseline conduction disease, procedural factors, and new ECG changes.
• Use monitoring long enough to capture delayed or intermittent arrhythmias.
• Define escalation rules for high-grade AV block, pauses, and atrial fibrillation.

Related Sensor Bio reading

• Single Lead Ecg Selection Cardiovascular Studies
• Atrial Fibrillation Wearable Screening
• Ppg Vs Ecg Vs Pulse Oximetry

Authoritative sources

• ACC TAVR conduction pathway
• AHA ambulatory ECG guidance
• PubMed TAVR conduction review

The trouble starts after the procedure. TAVR places a new valve right next to the heart’s electrical wiring. Swelling builds over the next 2 to 4 days and can press on those wires. Scar tissue forms over 2 to 4 weeks. Either one can trigger dangerous heart rhythm problems — and these can appear days or weeks after the patient gets home. The only reliable way to catch them is to keep a heart monitor on after TAVR.

In the best study we have on this topic, a 14-day patch monitor cut serious cardiac events by 71%.¹

Why Does TAVR Disrupt the Heart’s Electrical System?

Think of the heart’s electrical system like traffic lights: every chamber waits for its signal before it pumps. Those signals travel through a relay station that sits right next to where the new valve lands.

When the valve is placed, it presses on the nearby wiring. Swelling peaks at 48 to 96 hours after surgery.³ Scar tissue keeps forming for 2 to 4 weeks after that. Either one can block or slow the heart’s electrical signal. When the signal is fully blocked, the lower heart falls to 20 to 40 beats per minute — called complete heart block. Outside a hospital, that can be fatal within minutes.

What Heart Rhythm Problems Can Happen After TAVR?

Several types of rhythm problems can appear after the procedure, ranging from mild to life-threatening.²

• Left bundle branch block (LBBB): A block on the left side of the heart’s wiring. It shows up in 15 to 30% of TAVR patients and raises the risk of sudden death and heart failure.
• AV block: A signal that has trouble reaching the lower heart. Mild forms are common. Severe forms can cause fainting or cardiac arrest.
• Complete heart block: The signal is fully cut off. The lower heart beats on its own at 20 to 40 times per minute — a medical emergency.
• Atrial fibrillation (AFib): An irregular beat in the upper heart. It raises stroke risk and often causes no symptoms at all.

All of these can come and go. A clinic ECG might look perfectly normal even if the patient had a full heart block at 3 AM that same morning. Recording the heart’s rhythm around the clock is the only way to catch these events reliably.

What Did the RECORD Registry Find?

The RECORD registry is the strongest study on post-TAVR monitoring to date. Researchers tracked 1,217 TAVR patients at a high-volume heart center in France.¹ Two groups were compared:

• 211 patients wore a heart monitor patch for 14 days after discharge.
• 1,006 patients got standard care: a hospital monitor for one to two days, then nothing at home.

After one year, the gap was hard to ignore:

• Serious event rate in the monitored group: 1.9%
• Serious event rate in the standard-care group: 6.6%
• That is a 71% reduction in life-threatening cardiac events (p = 0.011).¹

The most striking finding: zero sudden cardiac deaths among the 211 patients who wore a patch. In the standard-care group, six patients died suddenly. A 14-day patch might have caught what killed them.¹

The Patch Also Found Hidden AFib

The monitor turned up new AFib in 8.9% of patch wearers. In the standard group, only 1.8% were identified.¹ Most of those patients felt nothing. The patch found it anyway.

Once found, 71% of those patients were started on blood thinners to lower stroke risk.¹ Without the monitor, their AFib would have gone undetected — and the stroke risk with it.

Who Is at the Highest Risk After TAVR?

Some patients face a much higher chance of wiring problems. These are the ones who need the closest watch.⁶

• Pre-existing right bundle branch block (RBBB): A block on the right side of the wiring before surgery. If TAVR also damages the left side, no backup path remains. Pacemaker risk can reach 40 to 60% in some studies.
• New LBBB after TAVR: When it appears alongside a slow conduction signal, there is a greater than 25% chance it worsens within 30 days.²
• Self-expanding valve type: Certain valve designs press harder on nearby tissue, which links them to higher pacemaker rates.
• Pre-existing first-degree AV block: A slow signal before surgery means the wiring was already under stress. TAVR can push it past the breaking point.

Why 48 Hours in the Hospital Is Not Enough

Most hospitals watch TAVR patients for 24 to 48 hours, then send them home. Here is the problem: swelling peaks at 48 to 96 hours after surgery.³ That is right when most patients walk out the door. Scar tissue keeps forming for 2 to 4 weeks after that.

A 24-hour recording captures only about 4% of the two-week risk window. A 14-day patch covers all of it.⁷ It runs at night while the patient sleeps, during a walk to the mailbox, during grocery shopping — no button to push, no log to keep. Low heart rate during sleep can be an early warning sign. Learn more about overnight heart rate patterns.

What Does a Heart Monitor Patch Look Like?

A heart monitor patch is roughly the size of a large bandage worn on the chest. It records every beat for up to 14 days while you sleep, walk, and go about your day — no button to push, no diary to keep. Data transmits automatically.

When the patch picks up a dangerous rhythm, an alert goes to a nurse or cardiologist. They can bring the patient in, order a pacemaker, or start blood thinners before something serious happens.

Who Should Get 14-Day Heart Monitoring After TAVR?

The RECORD registry supports 14-day monitoring for all TAVR patients.¹ Many programs begin with the highest-risk group: those with RBBB, new LBBB, or a slow conduction signal before surgery.

For patients with no risk factors and a normal ECG at 48 hours, most guidelines still recommend at least 7 days. If even one risk factor is present, the evidence points to the full 14 days.

For the full clinical version of this topic, see the post-TAVR ECG monitoring guide for clinicians.

The Bottom Line

TAVR saves lives. But the heart’s electrical system can stay at risk for weeks after the procedure is done. A 14-day monitor cuts serious events by 71% and may prevent sudden cardiac death.¹

If you or someone you care for has had TAVR, ask the cardiologist before discharge: “Should I wear a 14-day heart monitor?” Based on the strongest research we have, the answer is almost always yes.

References

1. Fischer Q, Rodés-Cabau J, et al. Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR: The RECORD Registry. Circulation: Cardiovascular Interventions. 2025. DOI: 10.1161/CIRCINTERVENTIONS.125.016288
2. Auffret V, Puri R, Urena M, et al. Conduction Disturbances after Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology. 2017;69(16):2066–2079. DOI: 10.1016/j.jacc.2017.01.062
3. Siontis GC, Juni P, Pilgrim T, et al. Predictors of Permanent Pacemaker Implantation in Patients with Severe Aortic Stenosis Undergoing TAVI: A Meta-Analysis. Journal of the American College of Cardiology. 2014;64(2):129–140. DOI: 10.1016/j.jacc.2014.04.033
4. Urena M, Hayek S, Cheema AN, et al. Arrhythmia Burden in Elderly Patients with Severe Aortic Stenosis as Determined by Continuous Electrocardiographic Recording. Circulation. 2015;132(17):1637–1644. DOI: 10.1161/CIRCULATIONAHA.115.016299
5. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay. Journal of the American College of Cardiology. 2019;74(7):932–987. DOI: 10.1016/j.jacc.2018.10.044
6. Mangieri A, Lanzillo G, Bertoldi L, et al. Predictors of Advanced Conduction Disorders Requiring Permanent Pacemaker Following Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions. 2020;13(5):581–591. DOI: 10.1016/j.jcin.2019.11.020
7. Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter Monitoring with 14-day Novel Adhesive Patch Electrocardiographic Monitoring. American Journal of Medicine. 2014;127(1):95.e11–17. DOI: 10.1016/j.amjmed.2013.10.003

Clinical Interpretation of Post-TAVR Ambulatory ECG Data

Post-TAVR ambulatory ECG monitoring serves two primary clinical objectives: detection of new conduction abnormalities, particularly high-degree atrioventricular block (AVB), and identification of new-onset atrial fibrillation (AF), which occurs in 15–30% of patients within 30 days of TAVR. The timing of these complications informs monitoring strategy. High-degree AVB most commonly manifests within 24–72 hours post-procedure, with risk concentrated in patients who develop new left bundle branch block (LBBB) on intra-procedural ECG — a finding associated with 3–5× elevated AVB risk compared to patients without new LBBB. Current ESC and ACC/AHA guidelines recommend at minimum 48–72 hours of continuous in-hospital telemetry for patients with new LBBB, and extended ambulatory monitoring for 30 days in patients discharged with persistent new conduction abnormalities.

Ambulatory ECG patch monitors used post-TAVR must support a minimum 14-day continuous recording duration to capture delayed conduction events. Devices should be evaluated on their R-wave detection sensitivity in the setting of LBBB morphology — the wide, notched QRS complex characteristic of LBBB can cause beat-detection algorithms trained on normal morphology to under-detect beats or misclassify rhythms. Validated algorithms for post-TAVR monitoring should demonstrate sensitivity ≥ 98% and specificity ≥ 96% for AF detection in the presence of LBBB morphology, as documented in the relevant device IFU or peer-reviewed validation studies. The absence of such validation data should be considered a contraindication to using a device for this specific clinical application.

Beyond arrhythmia detection, ambulatory ECG data following TAVR provides prognostically relevant information on heart rate variability and circadian rhythm restoration. Studies have shown that patients with preserved HRV parameters — specifically SDNN > 50 ms at 30 days — have significantly lower rates of major adverse cardiovascular events at 12-month follow-up compared to patients with depressed HRV, independent of LVEF. This finding supports incorporating HRV analysis into post-TAVR remote monitoring protocols, in addition to standard rhythm analysis. Wearable ECG platforms that combine single-lead rhythm monitoring with research-grade HRV analytics (RMSSD, pNN50, frequency-domain metrics) offer the most comprehensive post-TAVR monitoring capability currently available outside of a clinical research context.

Remote Monitoring Protocols and Follow-Up Timelines After TAVR

Structured remote monitoring programmes following TAVR have demonstrated measurable reductions in 30-day readmission rates when paired with clear escalation protocols. A prospective registry study published in the Journal of the American College of Cardiology reported a 23% reduction in unplanned cardiac readmissions among TAVR patients enrolled in a digital health programme that combined daily ECG patch transmission with automated arrhythmia alert delivery to the treating electrophysiology team, compared to standard care with scheduled outpatient visits. The programme’s success depended critically on two factors: device usability for elderly patients (mean age 79 years), and rapid response workflows with defined triage criteria for alert escalation versus watchful waiting.

Monitoring duration recommendations after TAVR continue to evolve with accumulating evidence. Current European consensus supports 30-day ambulatory monitoring for high-risk patients, defined as those with pre-existing conduction disease, post-procedural LBBB, or high-burden pre-operative atrial fibrillation. For lower-risk patients, a pragmatic 14-day monitoring window captures the majority of clinically relevant arrhythmic events while limiting patient burden. Remote ECG patch programmes specifically designed for post-TAVR monitoring differ from general Holter monitoring in their integration with cardiac surgery and structural heart disease care teams, their emphasis on conduction versus rhythm analysis, and their use of AI-assisted beat classification tuned to post-procedural ECG morphologies. Selecting an ambulatory ECG monitoring platform for a post-TAVR programme therefore requires close collaboration between structural heart teams, electrophysiology, and cardiac device specialists.

Patient Selection and Risk Stratification for Post-TAVR ECG Monitoring

Not all patients undergoing transcatheter aortic valve replacement carry equal risk for post-procedural conduction complications, and risk-stratified monitoring protocols offer both clinical and economic advantages over uniform 30-day monitoring for all patients. Key pre-procedural risk factors for new conduction abnormalities include pre-existing right bundle branch block (RBBB), PR interval prolongation greater than 200 ms, and the specific valve prosthesis design — self-expanding valves are associated with higher rates of permanent pacemaker implantation compared to balloon-expandable devices, reflecting the greater radial force exerted on the perimembranous interventricular septum and atrioventricular node during deployment. Patients with pre-existing RBBB carry a 20–30% risk of developing complete heart block during or after TAVR, compared to approximately 3–5% in patients without pre-existing conduction disease.

Intra-procedural predictors of post-TAVR conduction risk include new LBBB on departure from the catheterisation laboratory, greater prosthesis implantation depth relative to the non-coronary cusp, and larger prosthesis-to-annulus ratio. Centres with high-volume TAVR programmes increasingly use these variables to generate individualised risk scores that directly inform monitoring duration recommendations. Patients identified as high-risk based on these criteria are referred for extended 30-day ambulatory ECG monitoring with automated arrhythmia detection; those classified as low-risk with no new conduction findings at 48 hours may appropriately complete a 7–14 day monitoring period. This stratified approach reduces unnecessary monitoring burden on low-risk patients while ensuring adequate surveillance for those at elevated risk of delayed high-degree AVB, which can present as late as 7–14 days after TAVR in a small but clinically significant subset of patients.